Scientist-founders often believe one more experiment will prove their hypothesis. To succeed as a CEO, they must shift from scientific curiosity to ruthless capital discipline, killing unviable programs and building a team that challenges ideas, not just executes them.

David Solomon's career from academia to VC to CEO highlights a key formula for biotech leadership: combining a disciplined, scientific approach with savvy corporate finance to effectively translate good science into innovative medicines for patients.

A CEO's primary role differs fundamentally based on company type. In an asset-centric biotech, the CEO must act as a hands-on program manager, micromanaging execution. In a platform company, the CEO must be deeply embedded in the science to predict and leverage the technology's long-term trajectory.

Voyager's CEO Al Sandrock left academia for biotech because he felt powerless treating ALS patients. He accepted the constraints of corporate strategy to be part of a team that could develop impactful drugs, a common trade-off for physician-scientists seeking greater patient impact.

In the early stages, a biotech CEO's role is primarily scientific leadership and storytelling to attract investors. As the company and market mature, the role shifts. Effective CEOs must then become adaptable strategists, staying true to their core vision while responding to the dynamic industry environment.

Voyager CEO Al Sandrock, a physician-scientist, found his biggest challenge wasn't R&D but the business side. For pre-revenue biotechs, managing cash runway is the primary survival skill, requiring new CEOs to quickly learn finance from mentors and board members.

The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.

Archer's CEO conceptualizes his role as being in the 'time business.' He views capital raised as a representation of time for his team. His high-stakes travel and meetings are strategically chosen only if they secure outcomes that extend the company's runway, enabling the team to solve hard technical problems.

Beyond scientific knowledge, the most effective biotech CEOs possess a specific set of traits. They must be decisive, maintain ruthless capital discipline (even for small amounts), and consistently demonstrate strategic clarity, especially when facing the immense pressure inherent in the industry.